Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(03): 137-138
DOI: 10.4103/2278-330X.214583
ORIGINAL ARTICLE : Supportive Care and Others

Pattern of occurrence and treatment outcome of second primary malignancies: A single center experience

Prekshi Chaudhary
Department of Radiation Oncology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh
,
Sweety Gupta
Department of Radiation Oncology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh
,
Nitin Leekha
Department of Surgical Oncology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh
,
Ruchir Tandon
Department of Medical Oncology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh
,
Malay Nandy
Department of Medical Oncology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh
,
Sudarsan De
Department of Radiation Oncology, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Background: The incidence of cancer survivors is increasing, but these individuals, unfortunately, face the risk of second primary malignancies (SPMs). This increasing incidence can be credited to increased survival rates of cancer patients, environmental factors, host factors, and genetic predispositions. Hence, vigilance on the part of the patient as well as clinician for the development of new signs and symptoms is mandatory. Aims: Retrospective analysis of the pattern of incidence and clinical outcome of patients diagnosed with SPM and to review the literature. Settings and Design: A hospital-based retrospective collection of prospective data of patients diagnosed with SPM. Materials and Methods: Thirty-six patients with histopathologically proven SPM from January 2009 to July 2015 were included in this study. Factors such as age, sex, site, stage, histology, treatment received, and outcome were recorded. Statistical Analysis Used: Basic statistical tools have been used for analyzing the data. Results and Conclusions: The likelihood of occurrence of second malignancy, either synchronous or metachronous, should always be kept in mind while evaluating a cancer patient. Appearance of new signs and symptoms during the initial evaluation as well as during follow-up should raise a suspicion, and both patient and oncologist should have a low threshold for further assessment. Early diagnosis and treatment will reduce morbidity and mortality and lead to better survival outcome.

Key words

Cancer survivors - second primary malignancy - synchronous and metachronous dual malignancy


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Travis LB. Therapy-associated solid tumors. Acta Oncol 2002;41:323-33.
  • 2 Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship – Genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25.
  • 3 Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: Subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011;29:739-46.
  • 4 Warren S, Gates O. Multiple primary malignant tumors: A survey of the literature and statistical study. Am J Cancer 1932;16:1358-414.
  • 5 Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: A cohort study in the US SEER cancer registries. Lancet Oncol 2011;12:353-60.